Moody's Investors Service commented that a proposed amendment to Valeant Pharmaceutical International Inc.'s (NYSE: VRX) credit agreement will improve its liquidity position due to increased cushion under financial maintenance covenants. There is no impact on Valeant's ratings including the B2 Corporate Family Rating or the negative rating outlook.